Abstracts Archive - Page 2401 of 2425 - ACR Meeting Abstracts

Abstract Number: 329 • 2012 ACR/ARHP Annual Meeting
The SYK Inhibitor, Fostamatinib, Administered Alone or in Combination with Methotrexate in Rat Collagen-Induced Arthritis, Reduces Bone Erosions, Biomarkers of Cartilage/Bone Destruction, and Synovial Osteoclastogenic Cytokines
Polly Pine¹, Ayodele Apatira¹, Betty Y. Chang¹, Nathan Schoettler², Elliott B. Grossbard³ and Ernest Brahn², ¹Pharmacology, Rigel Pharmaceuticals, So San Francisco, CA, ²Rheumatology, UCLA School of Medicine, Los Angeles, CA, ³Rigel Pharmaceuticals, So San Francisco, CA
Background/Purpose: Spleen tyrosine kinase (SYK) is expressed in hematopoietic cells and is a major downstream regulator of signaling through Fcγ and immunoglobulin receptors as well…
Abstract Number: 289 • 2012 ACR/ARHP Annual Meeting
Mycophenolate Mofetil and Abatacept Combination Therapy in Refractory Pediatric Systemic Lupus Erythematosus Nephritis
Rhina Castillo¹, Suhas M. Radhakrishna², Andreas O. Reiff³ and Katherine AB Marzan¹, ¹Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ²Pediatric Rheumatology, Kaiser Permananete Medical Group, Oakland, CA, ³Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA
Background/Purpose: Nephritis (LN) in pediatric systemic lupus erythematosus (pSLE) requires treatment (tx) with corticosteroids (CS) and other agents such as mycophenolate mofetil (MMF) or cyclophosphamide…
Abstract Number: 290 • 2012 ACR/ARHP Annual Meeting
Long-Term Outcomes in Neonatal Lupus
Amit Saxena¹, Peter M. Izmirly², Deborah Friedman³ and Jill P. Buyon⁴, ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Division of Pediatric Cardiology, New York Medical College, Valhalla, NY, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Several studies have evaluated mortality and short-term morbidity in neonatal lupus (NL), however there have been no substantive descriptions of the long term cardiac,…
Abstract Number: 291 • 2012 ACR/ARHP Annual Meeting
Illness Features Associated with an Increased Risk of Mortality in Children with Juvenile Idiopathic Inflammatory Myopathies
Adam M. Huber¹, Gulnara Mamyrova², Julia A. Lee³, Peter A. Lachenbruch⁴, Ira N. Targoff⁵, Frederick W. Miller⁴, Lisa G. Rider⁴ and Childhood Myositis Heterogeneity Study Group⁶, ¹Dalhousie University, Halifax, NS, Canada, ²Rheumatology, George Washington University, Washington, DC, ³Environmental Autoimmunity Grp, NIEHS, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Bethesda, MD
Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are potentially life-threatening systemic autoimmune diseases but little in known regarding factors associated with mortality. Methods: Patients enrolled in…
Abstract Number: 292 • 2012 ACR/ARHP Annual Meeting
Clinical Utility of Anti-CADM-140/Melanoma Differentiation-Associated Gene 5 Autoantibody Titers in Patients with Juvenile Dermatomyositis and Rapidly Progressive Interstitial Lung Disease
Shinji Sato¹, Norimoto Kobayashi², Kazuko Yamazaki³ and Yasuo Suzuki⁴, ¹Rheumatology, Tokai University School of Medicine, Isehara, Japan, ²Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan, ³Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: The presence of anti-CADM-140/ (Melanoma Differentiation-Associated Gene 5: MDA5) autoantibody is specific for adult dermatomyositis (DM), especially in patients with little or no muscle…
Abstract Number: 293 • 2012 ACR/ARHP Annual Meeting
Usefulness of Cardiac Magnetic Resonance in the Assessment of Myocardial Inflammation and Fibrosis in Children Born to Mothers with Anti-SSA/Ro Antibodies: A Prospective Study of 23 Cases and 6 Controls
Nathalie Costedoat-Chalumeau¹, Alice Maltret², Kateri Levesque¹, Shelby Kutty³, Elisabeth Villain², Phalla Ou⁴ and Gaëlle Guettrot-Imbert⁵, ¹Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ²Cardiology, Groupe Hospitalier Necker - Enfants Malades, Paris, France, ³Division of Pediatric Cardiology, university of Nebraska Medical Center and Children's Hospital ans Medical Center, Omaha, NE, USA, Omaha, ⁴Radiology,, Groupe Hospitalier Necker - Enfants Malades, Paris, France, ⁵Internal Medicine, Hopital Gabriel Montpied, Clermont-Ferrand, France
Background/Purpose: Besides congenital heart blocks (CHB), others manifestations of cardiac neonatal lupus erythematosus syndrome (NLES) include endocardial fibroelastosis (EFE), and dilated cardiomyopathy. Recently, autopsy of…
Abstract Number: 294 • 2012 ACR/ARHP Annual Meeting
Effects of Obesity On Health-Related Quality of Life in Childhood-Onset Systemic Lupus Erythematosus
Rina Mina¹, Marisa S. Klein-Gitelman², Shannen Nelson³, Lori B. Tucker⁴, B. Anne Eberhard⁵, Nora G. Singer⁶, Deborah M. Levy⁷, Kathleen A. Haines⁸, Karen Onel⁹, Marilynn G. Punaro¹⁰, Kathleen M. O'Neil¹¹, Michael Henrickson¹², Jun Ying¹³ and Hermine Brunner¹⁴, ¹Rheumatology, Cincinnati Children's Hospital Medical Center/ University of Cincinnati, Cincinnati, OH, ²Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ⁴Pediatric Rheum/Rm K4-120, BC Childrens Hospital, Vancouver, BC, Canada, ⁵Cohen Children's Hospital Medical Center, New Hyde Park, NY, ⁶Medicine, Division of Rheumatology, MetroHealth Medical Center, Cleveland, OH, ⁷Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁸Department of Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ⁹Pediatric Rheumatology, University of Chicago, Chicago, IL, ¹⁰Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹¹Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ¹²MLC 4010, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Medicine-Internal Medicine-General Medicine, University of Cincinnati, Cincinnati, OH, ¹⁴Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Obesity in adults with Systemic Lupus Erythematosus (SLE) is associated with an added risk of cardiovascular disease, decreased health-related quality of life (HRQOL), and…
Abstract Number: 295 • 2012 ACR/ARHP Annual Meeting
Brain Biopsy Diagnosis in Magnetic Resonance Imaging Negative Childhood Primary Angiitis of the Central Nervous System
Senq-J Lee¹, Cynthia Hawkins², Suzanne Laughlin³, Shehla Sheikh⁴ and Susanne M. Benseler⁴, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ³Diagnostic Imaging, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Primary CNS vasculitis in childhood (cPACNS) is a devastating inflammatory brain disease mandating rapid and accurate diagnostic evaluation, in order to optimize neurologic outcomes. …
Abstract Number: 296 • 2012 ACR/ARHP Annual Meeting
A Brazilian Multicenter Study of 71 Children and Adolescents with Takayasu’s Arteritis
Maria Teresa Terreri¹, Gleice Clemente², Clovis Silva³, Silvana Sacchetti⁴, Adriana M. Sallum⁵, Lucia M. A. Campos⁶, Maria Carolina Santos⁴, Flavio Sztajnbok⁷, Rozana Gasparello de Almeida⁸, Virginia P. Ferriani⁹, Blanca E. Bica¹⁰, Teresa Robazzi¹¹, Marcia Bandeira¹², Andre Cavalcanti¹³, Marise Lessa¹⁴, Sheila K. Feitosa de Oliveira¹⁵ and Maria Odete Hilario¹⁶, ¹Pediatrics, Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, ²Pediatrics, Universidade Federal de São Paulo/UNIFESP, São Paulo, Brazil, ³Pediatric Rheumatology, MD; PhD, São Paulo-SP, Brazil, ⁴Pediatrics, Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo-SP, Brazil, ⁶Pediatric Rheumatology, University of São Paulo Medical School, São Paulo, Brazil, ⁷PRINTO, Genoa, Italy, ⁸Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹Pediatrics, FMUSP-Ribeirao Preto, Ribeirao Preto, Brazil, ¹⁰International Investigator Consortium for MAS Diagnostic Criteria, Rio de Janeiro, Brazil, ¹¹Pediatrics, Universidade Federal da Bahia, Salvador, Brazil, ¹²Pediatrics, Hospital Infantil Pequeno Príncipe, Curitiba, Brazil, ¹³Universidade Federal de Pernambuco, Recife, Brazil, ¹⁴Pediatrics, Instituto de Pediatria e Puericultura Martagão Gesteira (IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil, ¹⁵Pediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁶Pediatrics, Universidade Federal de Sao Paulo / UNIFESP, Sao Paulo, Brazil
Background/Purpose: Takayasu’s arteritis is a chronic granulomatous disease that affects the vascular wall of the large arteries and can result in end organ damage. It…
Abstract Number: 297 • 2012 ACR/ARHP Annual Meeting
Effectiveness of Intravenous Cyclophosphamide in Severe or Refractory Juvenile Dermatomyositis – A National Cohort Study: UK and Ireland
Elena Moraitis¹, Katie Arnold², Clarissa Pilkington³ and Juvenile Dermatomyositis Research Group⁴, ¹Rheumatology, Great Ormond Street Hospital, London, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, ³Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁴London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune vasculopathy affecting primarily the muscle and skin, but can also involve other organs. Early and aggressive treatment improves outcome and prevents complications. Cyclophosphamide has been used as a second-line agent in the treatment of severe or refractory JDM. The published literature on the effectiveness of cyclophosphamide in JDM is limited to a small case series and case reports.The objective of the study is to describe the response to cyclophosphamide in the patients with severe or refractory JDM. Methods: 56 patients treated with cyclophosphamide between years 2000-2011 were identified in the JDM National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. 8 patients were excluded due to incomplete data or too short follow up. For the 48 patients included, demographics, myositis core outcome variables, skin measures, laboratory measures, steroid dose and other treatments were recorded at baseline, time 6, 12, 18, 24 months and last follow up post commencement of the drug.Results: Indications for starting cyclophosphamide were ulcerative or severe skin disease, profound muscle weakness, lung disease, gastro-intestinal vasculopathy or refractory disease. Previous medications were steroids and Methotrexate for 47 patients and steroids and Cyclosporin for 1 patient. All patients starting with muscle weakness (n=44) significantly improved at time12, and the gains were maintained at follow up (see table1). Physician VAS was available for 32 patients and these all improved by 12 and 24 months, and for 31 remained stable at follow up. At last follow up 26/46(56%) had no rash, 32/46(69%) had normal nailfolds, 37/45(82%) had no Gottron’s, and calcinosis improved in 9/14(64%). Conclusion: This study, the largest to date, demonstrated significant improvement in both muscle and skin domains in patients with JDM treated with intravenous cyclophosphamide.Cyclophosphamide appears effective in the treatment of severe or refractory JDM.Table 1Table 2
Abstract Number: 298 • 2012 ACR/ARHP Annual Meeting
Childhood-Onset Predicts Increased Disease Damage and Steroid Toxicity in a Cohort of Adults with Systemic Lupus Erythematosus
Erica F. Lawson¹, Laura Trupin², Jinoos Yazdany³, Aimee Hersh⁴, Emily von Scheven⁵ and Edward H. Yelin⁶, ¹Pediatrics, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Pediatrics, University of Utah, Salt Lake City, UT, ⁵Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ⁶Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: While previous work has shown that adults with childhood-onset systemic lupus erythematosus (cSLE) have increased risk of mortality, renal disease and myocardial infarction as…
Abstract Number: 299 • 2012 ACR/ARHP Annual Meeting
Reduction of Cerebral and Corpus Callosum Volumes in Childhood-Onset Systemic Lupus Erythematosus. A Volumetric Magnetic Resonance Imaging Analysis
Aline T. Lapa¹, Wesley G. Ferreira¹, Mariana Postal¹, Nailu A. Sinicato¹, Roberto Marini², Fernando Cendes³ and Simone Appenzeller⁴, ¹Medicine, State University of Campinas, Campinas, Brazil, ²State University of Campinas, Campinas, Brazil, ³Neurology, State University of Campinas, Campinas, Brazil, ⁴Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose: Cerebral atrophy has been described to occur in SLE with variable frequency. Aging, systemic diseases, corticosteroid use and central nervous system (CNS) involvement may…
Abstract Number: 300 • 2012 ACR/ARHP Annual Meeting
Prevalence and Clinical Significance of Hippocampal Atrophy in Childhood-Onset Systemic Lupus Erythematosus
Aline T. Lapa¹, Renata Brabosa², Mariana Postal¹, Nailu A. Sinicato¹, Roberto Marini³, Fernando Cendes⁴ and Simone Appenzeller⁵, ¹Medicine, State University of Campinas, Campinas, Brazil, ²Medicine, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Germany, ³State University of Campinas, Campinas, Brazil, ⁴Neurology, State University of Campinas, Campinas, Brazil, ⁵Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose: Hippocampal atrophy is associated with corticosteroid use and may be related to cognitive impairment in systemic lupus erythematosus (SLE).Objectives: To determine the prevalence of…
Abstract Number: 301 • 2012 ACR/ARHP Annual Meeting
Decreased Frequency of Dystrophic Calcifications in Children with Juvenile Dermatomyositis: A 10-Year Study
Lauren M. Pachman¹, Gabrielle A. Morgan², Megan L. Curran¹, Lori J. Ferguson³ and Chiang-Ching Huang⁴, ¹Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Cure JM Myositis Center, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center, Chicago, IL, ³Children's Hospital of Chicago Research Center, Cure JM Myositis Center, Chicago, IL, ⁴Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: In Juvenile Dermatomyositis (JDM), dystrophic calcifications, associated with increased morbidity and mortality, have been reported for 20-30% of patients. There are few laboratory indicators…
Abstract Number: 302 • 2012 ACR/ARHP Annual Meeting
Accuracy of Systemic Lupus International Collaborating Clinics Classiffication Criteria Applied to Juvenile Systemic Lupus Erythematosus Patients
Marìa M. Katsicas¹, Ezequiel Borgia², Ileana Villarroel² and Ricardo Russo³, ¹Service of Immunology & Rheumatology. Hospital de Pediatrìa Prof Dr.Juan.P. Garrahan, MD, Buenos Aires, Argentina, ²Service of Immunology & Rheumatology. Hospital de Pediatrìa Prof Dr.Juan.P. Garrahan, MD, Caba, Argentina, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototype autoimmune disease. The most widely used classification criteria for SLE were those developed by the American College…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].